Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

iota Biosciences

http://iota.bio

Latest From iota Biosciences

Astellas Eyes Doubling Market Cap On Core, Focus Assets

Astellas lays out new mid-term strategic plan it sees as overcoming looming major expiries while positioning the firm for growth in new areas and a more than doubling in market cap.

Business Strategies Commercial

Beyond The Pandemic, An Interview With Astellas’ Percival Barretto-Ko

Astellas Pharma US accounts for roughly one-third of the parent company’s annual revenues with a growing focus on immuno-oncology. The unit’s president discusses lessons from the pandemic, racial disparities in health care and business development.

Business Strategies Coronavirus COVID-19

Astellas Pays $300m+ For iota In ‘Pharma-Plus’ Push

Japanese major builds presence in novel device technology beyond its conventional therapeutics as looks towards a more holistic future of care. 

Commercial Platform Technologies
See All

Company Information

  • Industry
  • Digital Health
  • Medical Devices
    • Implantable Devices
    • Monitoring Equipment & Devices
    • Diagnostic Imaging Equipment & Supplies
      • Ultrasound
  • In Vitro Diagnostics
    • Biosensors
UsernamePublicRestriction

Register